EW
NVS icon

Elyxium Wealth’s Novartis NVS Stock Holding History

Elyxium Wealth’s Portfolio NVS Stock Details NVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$278K Sell
1,820
-982
-35% -$151K 0.09% 139
2025
Q4 		$386K Buy
2,802
+240
+9% +$31.4K 0.11% 123
2025
Q3 		$329K Buy
+2,562
New +$313K 0.11% 131

Other funds holding NVS

Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Elyxium Wealth's NVS Position: Q1 2026 in Review

Elyxium Wealth reduced its Novartis (NVS) stake by 35% in Q1 2026, selling an estimated $151K and leaving 1,820 shares worth $278K. The position accounts for 0.09% of the portfolio, ranked #139.

Elyxium Wealth first reported a position in NVS in Q3 2025 and has held it in 3 quarters since. The position peaked at $386K in Q4 2025. 1,590 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

  • Elyxium Wealth held 1,820 shares of Novartis worth $278K as of Q1 2026.
  • Elyxium Wealth sold 982 Novartis shares in Q1 2026, an estimated $151K.
  • Novartis made up 0.09% of Elyxium Wealth's portfolio in Q1 2026, its #139 holding.
  • Elyxium Wealth first reported a position in Novartis in Q3 2025 and has held it in 3 quarters since.
  • Elyxium Wealth's Novartis position peaked at $386K in Q4 2025.
  • 1,590 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on Elyxium Wealth's 13F filing for Q1 2026, filed 6 May 2026.